Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for Capricor Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($1.33) per share for the year, up from their prior forecast of ($1.38). HC Wainwright has a "Buy" rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics' Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.
Several other equities analysts have also recently commented on CAPR. Maxim Group raised their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Oppenheimer restated an "outperform" rating and set a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald increased their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $34.50.
Read Our Latest Research Report on CAPR
Capricor Therapeutics Price Performance
NASDAQ CAPR traded down $0.23 on Monday, hitting $18.38. The company had a trading volume of 1,216,143 shares, compared to its average volume of 1,147,849. Capricor Therapeutics has a 12-month low of $2.87 and a 12-month high of $23.40. The company's fifty day moving average price is $15.21 and its 200-day moving average price is $8.50. The company has a market capitalization of $834.56 million, a PE ratio of -17.34 and a beta of 4.00.
Insider Activity at Capricor Therapeutics
In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm's stock in a transaction dated Friday, September 20th. The stock was bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 12.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Capricor Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. BNP Paribas Financial Markets bought a new position in Capricor Therapeutics during the 1st quarter worth approximately $40,000. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $161,000. Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the 3rd quarter worth approximately $192,000. Finally, FMR LLC bought a new position in Capricor Therapeutics during the third quarter valued at approximately $370,000. 21.68% of the stock is owned by institutional investors and hedge funds.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
